Hematopoietic cell transplantation after CD19-directed CAR T-cell therapy for remission consolidation or relapse treatment in pediatric acute lymphoblastic leukemia
Retrospective analysis shows HCT improves outcomes in young adults with B-ALL after CAR T-cell therapy, indicating relapse prevention and therapy benefits.
Key Points
Hematopoietic cell transplantation led to a 90% disease-free survival in the preemptive cohort at three years, compared to 64% in the relapse cohort.
The cumulative incidence of grade III-IV acute graft-versus-host disease was 14% and 19% in preemptive and relapse cohorts, respectively.
Retrospective review analyzed 47 young adults with B-ALL undergoing first HCT after CAR T-cell therapy for remission consolidation or relapse therapy.
These findings highlight the effectiveness of HCT for durable B-ALL remission and call for further investigation of long-term outcomes.